EUVIMEDEUVIMED entdecken
EvaluationsstudieOpen Access · CC BY 4.0

Diagnostic accuracy and inter-lot precision of the FujiLAM II point-of-care assay to detect tuberculosis in stored urine specimens from people living with HIV

Nestor Biatu iD, Cyrille Mbuli iD, Comfort Vuchas iD, Rita Nsamenang, Nadege Bonkar Chifu, Asonganyi Etiendem, Diana Kolieghu Tcheumeni iD, Angela Neh iD, Ngha Ndze Mbuh iD, Nadia Kontogianni, Rachel Owen iD, Ndi Norah Nyah iD und 5 weitere

Microbiology Spectrum · 04.08.2026 · 14 (8)

DOI: 10.1128/spectrum.00620-26 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift Microbiology Spectrum, erschienen am 04.08.2026. Verfasst von Nestor Biatu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Promotion and Research, Bamenda, Cameroon. Hauptthemen laut MEDLINE: HIV Infections, Tuberculosis, Mycobacterium tuberculosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Fujifilm SILVAMP TB LAM II (FujiLAM II) assay is a lateral flow assay that detects TB from urine specimens. This updated version of the assay has been redesigned to address inter-lot variability issues of the original FujiLAM assay. We evaluated the diagnostic accuracy and inter-lot variability of the FujiLAM II assay on biobanked urine specimens collected from inpatients and outpatients living with HIV in two prospective studies conducted at hospitals in Cameroon. Diagnostic performance was evaluated against microbiological reference standards and compared to the Determine TB LAM Ag (AlereLAM) test and smear microscopy. From January to March 2025, urine specimens from 798 people with HIV were tested and analyzed, including 128 (16%) with microbiologically confirmed TB. Against a microbiological reference standard including two sputum liquid cultures and sputum, urine, and blood Xpert Ultra, the sensitivity of the FujiLAM II was 49% (58/119, 95% CI 40%–58%) as compared to 35% (42/119, 95% CI 27%–44%) on the AlereLAM, and the specificity of FujiLAM II was 96% (621/650, 95% CI 94%–97%) as compared to 92% (601/650, 95% CI 90%–94%) on the AlereLAM. Among a subset of 161 participants with any TB result positive, positivity across four manufacturing lots ranged from 37% (60/161, 95% CI 30%–45%) to 42% (67/161, 95% CI 34%–49%), with no significant difference across lots (Cochran’s Q = 4.2, P = 0.2). These results suggest the FujiLAM II assay has the potential to improve TB diagnosis in some populations, as compared to the only currently available LAM test. IMPORTANCE Many people with TB are never diagnosed with and treated for the disease. While sputum-based tests for TB based on molecular diagnostics are highly sensitive, there are many barriers to access due to the high cost and infrastructure requirements of these tests. Accurate, point-of-care tests that can be conducted in peripheral settings without equipment and on non-sputum specimens have the potential to greatly increase access to TB testing and close this gap in care. The Fujifilm SILVAMP TB LAM II test is a new urine-based lateral flow test for TB. Our results show that this test is more sensitive to detect TB in people living with HIV than the only currently recommended urine point-of-care TB test and that the test has consistent performance across lots.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTuberculosisMycobacterium tuberculosisHumansSensitivity and SpecificityProspective StudiesFemaleMaleRapid Diagnostic TestsAdultCameroonPoint-of-Care SystemsSputumPoint-of-Care TestingMiddle Aged

Stichwörter der Autor:innen

Mycobacterium tuberculosisdiagnosticspoint of care

Autor:innen und Institutionen

  • Center for Health Promotion and Research, Bamenda, Cameroon.
  • Liverpool School of Tropical Medicine, Liverpool, England, United Kingdom.
  • Cameroon Baptist Convention Health Service, Bamenda, Northwest Region, Cameroon.
  • Friends for International TB Relief, Hanoi, Vietnam.
  • Department of Global Public Health, Karolinska Institute, Stockholm, Sweden.
  • Stop TB Partnership, Geneva, Switzerland.

ORCID-Profile: Nestor Biatu, Cyrille Mbuli, Comfort Vuchas, Diana Kolieghu Tcheumeni, Angela Neh, Ngha Ndze Mbuh, Rachel Owen, Ndi Norah Nyah, Melissa Sander, Ana Isabel Cubas Atienzar

Zitieren

APA

Biatu, N., Mbuli, C., Vuchas, C., Nsamenang, R., Chifu, N. B., Etiendem, A., Tcheumeni, D. K., Neh, A., Ndze Mbuh, N., Kontogianni, N., Owen, R., Norah Nyah, N., Quang Vo, L. N., Codlin, A., Creswell, J., Sander, M., & Cubas Atienzar, A. I. (2026). Diagnostic accuracy and inter-lot precision of the FujiLAM II point-of-care assay to detect tuberculosis in stored urine specimens from people living with HIV. Microbiology Spectrum, 14(8). https://doi.org/10.1128/spectrum.00620-26

Vancouver

Biatu N, Mbuli C, Vuchas C, Nsamenang R, Chifu NB, Etiendem A, et al. Diagnostic accuracy and inter-lot precision of the FujiLAM II point-of-care assay to detect tuberculosis in stored urine specimens from people living with HIV. Microbiology Spectrum. 2026;14(8). doi:10.1128/spectrum.00620-26

BibTeX
@article{Biatu2026,
  author = {Biatu, Nestor and Mbuli, Cyrille and Vuchas, Comfort and Nsamenang, Rita and Chifu, Nadege Bonkar and Etiendem, Asonganyi and Tcheumeni, Diana Kolieghu and Neh, Angela and Ndze Mbuh, Ngha and Kontogianni, Nadia and Owen, Rachel and Norah Nyah, Ndi and Quang Vo, Luan Nguyen and Codlin, Andrew and Creswell, Jacob and Sander, Melissa and Cubas Atienzar, Ana Isabel},
  title = {Diagnostic accuracy and inter-lot precision of the FujiLAM II point-of-care assay to detect tuberculosis in stored urine specimens from people living with HIV},
  journal = {Microbiology Spectrum},
  year = {2026},
  volume = {14},
  number = {8},
  doi = {10.1128/spectrum.00620-26}
}
Kostenlos starten →